159 results
Page 2 of 8
6-K
tfoc2tj33f
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
uqc5qu
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
5d9dnil4
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
ihptiduw
30 May 23
Current report (foreign)
6:11am
6-K
59zl404gu662r5ic5wt1
17 May 23
Current report (foreign)
6:02am
6-K
ddv7sy vmxqt5xuw
11 May 23
Current report (foreign)
6:10am
6-K
opzu8pvylsoqh
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
787pe
11 May 23
Current report (foreign)
6:07am
6-K
7jypg93ef 4avc
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
7jkxlg
21 Dec 22
Current report (foreign)
6:01am
6-K
u0rv4jn93vm3po1dm5le
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
mb8tj2i mtcx6f
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
x9rg2m
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
rl9ef53r40r1eo
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
9xcuz 9rn0etg
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
50orj
27 Oct 22
Current report (foreign)
6:01am
6-K
38l2kc6hhi1f
14 Oct 22
Current report (foreign)
7:36am
6-K
3k6t6h8u8xbyvka
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
6v6np sx06eiagmw
23 Aug 22
Current report (foreign)
6:13am